Why Did Investors Lose Faith In Immutep Stock (IMMP) Today?

Immutep (IMMP) stock fell hard on Friday after the biotechnology company announced it would discontinue a Phase III clinical trial. This study was focused on eftilagimod alfa, a treatment in development to treat patients with first-line non-small cell lung cancer.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

• Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

Immutep said that it will stop enrollment in the study and wind it down on the recommendation of the Independent Data Monitoring Committee (IDMC) for the trial. This recommendation was made following an interim futility analysis of the trial. The IDMC reached a discontinue-due-to-futility conclusion after going over the safety and efficacy data for the trial.

Marc Voigt, CEO of Immutep, said, “We are very disappointed and surprised with the outcome of the futility analysis, in light of efti’s performance in every other clinical trial. We would like to thank the patients, investigators, and clinical teams who contributed to this important study. We are currently conducting a comprehensive review of the available data to better understand the results and determine the appropriate next steps for the program.”

What’s Next for Immutep?

Immutep said it will continue to focus on the other candidates in its pipeline following the end of this Phase III clinical trial. It also noted that with the end of this trial, the company’s cash runway has been extended to Q2 2027. Immutep intends to provide an updated outlook on its revised cash runway and will reassess capital allocation priorities once it’s done closing down the eftilagimod alfa study.

Investors Lose Faith in Immutep Stock

Immutep’s decision to end its clinical trial was a major blow to investor morale. This saw the stock plummet 79.26% in pre-market trading on Friday, following a 1.1% rally yesterday. The shares were down 3.5% year-to-date but were up 55.06% over the past 12 months.

Today’s news also appears to have triggered a selloff of IMMP stock, as more than 11 million shares have changed hands this morning. That’s well above the company’s three-month average daily trading volume of about 154,000 shares.

Is Immutep Stock a Buy, Sell, or Hold?

Turning to Wall Street, the analysts’ consensus rating for Immutep is Hold, based on two Hold ratings over the past three months. There currently isn’t an average price target for IMMP stock.

Disclaimer & DisclosureReport an Issue